



CONTACTS

Telephone
+39 340 7863295

Websites
<https://orcid.org/0000-0002-8915-0755>
https://www.researchgate.net/profile/Giovanni_Adami2

<https://www.scopus.com/authid/detail.uri?authorId=57055305200>

Emails
giovanni.adami@univr.it (principal)
adami.q@yahoo.com

Certified email
giovanni.adami@pec.omceovr.it

Work address:
Piazzale L.A. Scuro, 10, 37134
Verona VR – UOC di Reumatologia,
Università degli Studi di Verona

Home address:
Via Santini 68/A, 37124 Verona VR

Curriculum Vitae

DR. GIOVANNI ADAMI

MD, PhD

EDUCATION AND TRAINING

Liceo Scientifico Girolamo Fracastoro

2004 - 2009
High School

Università di Verona – Medical School

2009 – 14-07-2015
Doctor of Medicine (MD)
Vote: magna cum laude (110/110 L)
Thesis: "Short-Term Effects of TNF Inhibitors on Bone Turnover Markers and Bone Mineral Density in Rheumatoid Arthritis"

University of Verona, Rheumatology Division

2016 – 12-11-2020
Rheumatologist
Vote: magna cum laude (70/70 L)
Thesis: "Risk of fragility fractures in obesity, diabetes and glucocorticoid requiring diseases: a retrospective analysis on a nation-wide cohort"

University of Verona, Department of Medicine, Rheumatology Division

2020 – 2023
PhD in Clinical and Experimental Biomedical Sciences at the University of Verona, focus on metabolic bone diseases and inflammatory arthritides
Thesis: "Influence of Air Pollution of Rheumatological Diseases"

University of Verona, Department of Medicine, Rheumatology Division

2025-ongoing
Assistant Professor - Tenure Track Researcher (RTT) MEDS-09/C - Rheumatology
Teaching activities in Combined Bachelor's + Master Degree in Medicine and Surgery

Habilitation to medical profession

04-02-2016 – OMCEOVR 08783

Habilitation for associate professor in Rheumatology

17-12-2023 – 17-12-2034
obtained the National Scientific Qualification for the role of Associate Professor in the Competition Sector 06/D3 - BLOOD DISEASES, ONCOLOGY, AND RHEUMATOLOGY

PROFESSIONAL EXPERIENCES

University of Verona, Department of Medicine, Rheumatology Division

2016 - ongoing
I deal with rheumatological pathologies both in the clinic and in the ward. I managed patients suffering from chronic rheumatological diseases at the Rheumatology Unit coordinated by Prof. Maurizio Rossini. I have gained experience in managing patients suffering from numerous rheumatological and osteometabolic pathologies, I am able to independently perform and report rheumatological musculoskeletal ultrasound. I have developed

excellent clinical and care skills, receiving proofs of esteem from both colleagues and patients.

Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB), United States, AL – Research Fellow
04/2018 – 04/2019

I spent a year as a Research Fellow in the United States, mentor Prof Kenneth G Saag, who is an international expert in bone metabolism, glucocorticoid induced osteoporosis, rheumatoid arthritis and gouty arthritis. I saw clinical trial patients in an NIH funded study investigating whether mycophenolate mofetil may attenuate immunogenicity when using PEGylated uricase in patients with severe refractory gout. I also investigated factors associated with bisphosphonate “drug holidays”, a question of profound importance in clinical care, using large databases available at UAB (through the Pharmacology Epidemiology and Economics Research Group (PEER), led by co-mentor Jeffrey Curtis, MD, MPH, MS, and William J. Koopman Professor of Medicine) including administrative data (US Medicare) and large cohort data from the well-known GLOW and PAADRN studies. From this project, I published a paper as first author in the Journal of Bone and Mineral Research (a high impact journal in the field of osteoporosis) and gave oral presentations at EULAR and IOF/WCO/ESCEO.

I took epidemiology and biostatistics courses in the UAB School of Public Health and participated in enrichment activities including all study team research meetings, Rheumatology Grand Rounds, COERE Works-in-Progress conference series. I also attended “Friday Fellows” Meetings, a weekly seminar series aimed at providing career guidance (e.g. grant writing skills, presentation practicums, and learning to critically analyze data) for fellows on NIH research training grants supported by both the UAB NIH funded Center of Translation Science Awards (CTSA) TL1 and the Agency for Health Care Research and Quality T32 in Health Services Research. I was involved in the writing of two grants: one Investigator Initiated Study (IIS) on Denosumab discontinuation and a P50 grant on gout care improvement. Both studies have subsequently been funded.

During my stay at the University of Alabama at Birmingham I produced 3 original articles and 6 review articles.

KEY ACHIEVEMENTS AND QUALIFICATIONS

Research

I am the author of 140 scientific papers published in peer-reviewed international journals and indexed in English. I am the first author in 54 of these scientific papers and second, last or corresponding author in numerous others. I have >2400 citations. I have gained experience in writing research protocols and funding calls. Scopus H-index = 27. Google Scholar H-index = 31. Google Scholar i10-Index = 66

Please find attached to the present CV my publication list.

I am young author, together with prof. Maurizio Rossini e prof. Roland Chapurlat, of the module “Osteoporosis: Pathogenesis and Clinical features” of “The EULAR Textbook on Rheumatic Diseases (2020)” and “EULAR on-line course on Rheumatic Diseases (2020)”

I am author of the guidelines of the Istituto Superiore di Sanità “Diagnosi, stratificazione del rischio e continuità assistenziale delle Fratture da Fragilità” of the FRAME group. Guidelines developed with the GRADE method following the ISS “Manuale metodologico per la produzione di linee guida di pratica clinica” elaborated by the “Centro Nazionale per l’Eccellenza Clinica, la Qualità e la Sicurezza delle Cure (SNLG ISS, 2019)”.

I am author of the guidelines of the Istituto Superiore di Sanità “Vaccinazioni nelle malattie reumatologiche infiammatorie e autoimmuni” of the SIR (Italian Society of Rheumatology) group. Guidelines developed with the GRADE

method following the ISS “Manuale metodologico per la produzione di linee guida di pratica clinica” elaborated by the “Centro Nazionale per l’Eccellenza Clinica, la Qualità e la Sicurezza delle Cure (SNLG ISS, 2019)”.

I am co-author of the “Unireuma” textbook on rheumatic musculoskeletal diseases of the Italian Society of Rheumatology. Chapter on “Osteoporosis diagnosis and treatment”.

I am co-author of the “Rheumatology” textbook on rheumatic musculoskeletal disease Rheumatology, 2-Volume Set 9th edition - Editors: Marc C. Hochberg, Ellen M. Gravallese, Josef S. Smolen, Desiree van der Heijde, Michael E. Weinblatt, Michael H. Weisman. Chapter on “Glucocorticoids” co-authors Kenneth G Saag and Frank Buttigereit

I am convenor of the EULAR project QoC026 for the development of recommendations for the screening and management of osteoporosis in patients with inflammatory rheumatic musculoskeletal diseases (iRMDs)

I am associate editor of Therapeutic Advances in Musculoskeletal Diseases (SAGE) and review editor in Frontiers in Endocrinology

I am associate editor of Rheumatology (Oxford)

Communication skills

I am lecturer at grand round at the Division of Rheumatology, Temple University (Philadelphia, US) and at the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (Birmingham, US).

I have participated in numerous national and international meetings and congresses as a moderator or invited speaker.

I was able to present the scientific work I produced in national congresses and meetings (Italian Society of Rheumatology, SIR; Italian Society of Osteoporosis and Mineral Metabolism and Skeletal Diseases, SIOMMMS; Italian Society of Orthopedics, Medicine and Rare Diseases of skeleton, SIOM-ORTOMED) and international (European League Against Rheumatisms, EULAR; International Osteoporosis Foundation, World Congress of Osteoporosis, IOF/WCO; European Calcified Tissue Society, ECTS, American Society of Bone and Mineral Research, ASBMR, Japan Society of Bone and Mineral Research, JSBMR; Spanish Society of Rheumatology, SER; Spanish Society of Bone and Mineral Research, SEIOMMM). Below are some relevant oral communications on original studies (not invited) that I gave (more than 100 oral presentations overall – invited or awarded).

- SIR 2019 oral communication entitled: “VARIAZIONI DEL METABOLISMO MINERALE OSSEO IN CORSO DI TERAPIA CON ANTI-TNF IN PAZIENTI AFFETTI DA ARTRITE”
- EULAR 2019 oral communication entitled: “TEMPORAL TRENDS OF BISPHOSPHONATE DISCONTINUATION AND FACTORS ASSOCIATED WITH ALENDRONATE DISCONTINUATION AND RESTART AT POPULATION LEVEL”
- EULAR 2019 oral communication entitled: “EFFECTIVENESS OF INFLUENZA VACCINE IN TNF INHIBITORS TREATED PATIENTS”
- SIR 2019 oral communication entitled: “CHANGES IN DKK-1, SCLEROSTIN, AND RANKL SERUM LEVELS FOLLOWING DISCONTINUATION OF LONG-TERM DENOSUMAB TREATMENT IN POSTMENOPAUSAL WOMEN”
- SIR 2019 oral communication entitled: “REMS (RADIOFREQUENCY ECOGRAPHIC MULTI SPECTROMETRY) PER LA VALUTAZIONE DELLA PROBABILITÀ DI FRATTURA: RISULTATI DI UNO STUDIO OSSERVAZIONALE FINO A 5 ANNI DI FOLLOW UP”
- SIOM-ORTOMED oral Communication 2019 entitled: “REMS (RADIOFREQUENCY ECOGRAPHIC MULTI SPECTROMETRY) PER LA VALUTAZIONE DELLA PROBABILITÀ DI FRATTURA:

RISULTATI DI UNO STUDIO OSSERVAZIONALE FINO A 5 ANNI DI FOLLOW UP"

- GISMO 2019 oral communication entitled: "DIFFERENT BASELINE PROFILE OF RISK OF FRACTURE IN PATIENTS TREATED WITH ANTI-OSTEOPOROTIC DRUGS IN REAL-LIFE"
- IOF/WCO 2020 oral communication entitled: "TEMPORAL TRENDS OF BISPHOSPHONATE DISCONTINUATION AND FACTORS ASSOCIATED WITH ALENDRONATE DISCONTINUATION AND RESTART AT POPULATION LEVEL"
- SIR 2020 oral communication entitled: "RISK OF FRAGILITY FRACTURES IN OBESITY AND DIABETES: A RETROSPECTIVE ANALYSIS ON A NATION-WIDE COHORT"
- SIR 2020 oral communication entitled: "RISK OF FRAGILITY FRACTURES IN DIFFERENT GLUCOCORTICOID REQUIRING DISEASES: A PROPENSITY SCORE MATCHING ANALYSIS"
- ACR Convergence 2020 oral communication entitled: "CENTRAL SENSITIZATION IS AN INDEPENDENT DETERMINANT OF FUNCTIONAL DISABILITY IN INFLAMMATORY ARTHRIDES"
- EULAR 2020 oral presentation entitles "FACTORS ASSOCIATED WITH OSTEOPOROSIS CARE OF MEN: A REAL-LIFE STUDY ON A NATION-WIDE DATASET"
- EULAR 2020 oral presentation and clinical abstract winner entitled: "ASSOCIATION BETWEEN ENVIROMENTAL AIR POLLUTION EXPOSURE AND FLARES IN RHEUMATOID ARTHRITIS"
- IOF-WCO-ESCEO 2021 oral presentation entitled: "RISK OF FRAGILITY FRACTURES IN GLUCOCORTICOID REQUIRING DISEAES"
- SIOT 2021 oral presentation entitled: "ASSOCIATION BETWEEN EXPOSURE TO PARTICULATE MATTER AND OSTEOPOROSIS, A POPULATION STUDY"
- ECTS 2021 oral presentation entitled: "ASSOCIATION BETWEEN ENVIROMENTAL AIR POLLUTION EXPOSURE AND FLARES IN RHEUMATOID ARTHRITIS"
- ECTS 2021 oral presentation entitled: "RISK OF FRAGILITY FRACTURES IN GLUCOCORTICOID REQUIRING DISEAES"
- LUPUS-CORA 2021 oral presentation entitled: "ASSOCIATION BETWEEN EXPOSURE TO PARTICULATE MATTER AND OSTEOPOROSIS, A POPULATION STUDY"
- SIR 2021 oral communication entitled: "ASSOCIATION BETWEEN EVIROMENTAL AIR POLLUTION AND OSTEOPOROSIS, A NATION-WIDE POPULATION ANALYSIS"
- IOF-WCO-ESCEO 2022 oral communication entitled: "ASSOCIATION BETWEEN EXPOSURE TO FINE PARTICULATE MATTER AND OSTEOPOROSIS: A POPULATION BASED COHORT STUDY"
- ECTS 2022 oral communication entitled: "REAL-LIFE SHORT-TERM EFFECTIVENESS OF ANTI-OSTEOPOROTIC TREATMENTS: A LONGITUDINAL COHORT STUDY"
- ECTS 2022 oral communication entitled: "ASSOCIATION BETWEEN EXPOSURE TO FINE PARTICULATE MATTER AND OSTEOPOROSIS: A POPULATION BASED COHORT STUDY"
- EULAR 2022 oral communication entitled: "REAL-LIFE SHORT-TERM EFFECTIVENESS OF ANTI-OSTEOPOROTIC TREATMENTS: A LONGITUDINAL COHORT STUDY"
- EULAR 2022 oral communication entitled: "ASSOCIATION BETWEEN EXPOSURE TO FINE PARTICULATE MATTER AND OSTEOPOROSIS: A POPULATION BASED COHORT STUDY"
- EULAR 2022 oral communication plenary abstract session entitled: "ASSOCIATION BETWEEN EXPOSURE TO FINE PARTICULATE MATTER AND IMMUNE-MEDIATED DISEASES (IMIDs): A POPULATION BASED COHORT STUDY"

- SIOMMMS 2022 oral communication entitled: "SHORT-TERM (2-YEARS) FRACTURE RISK PREDICTION: A MACHINE LEARNING APPROACH"
- SIR 2022 oral communication entitled: "SHORT-TERM (2-YEARS) FRACTURE RISK PREDICTION: A MACHINE LEARNING APPROACH"
- ACR 2022 oral communication (late breaking abstract – plenary session) entitled: "IMPACT OF GLUCOCORTICOID DOSING AND ANTI-OSTEOPOROTIC TREATMENT ON BONE HEALTH IN PATIENTS WITH INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISEASES: A LONGITUDINAL COHORT STUDY"
- ECTS 2023 oral communication entitled: "LONG-TERM EFFECTIVENESS AND PREDICTORS OF NERIDRONATE TREATMENT IN TYPE I COMPLEX REGIONAL PAIN SYNDROME (CRPS)"
- ECTS 2023 oral communication entitled: "TAPERING GLUCOCORTICOIDS AND RISK OF FLARE IN RHEUMATOID ARTHRITIS ON BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS (BDMARDs)"
- ECTS 2023 oral communication entitled: "IMPACT OF GLUCOCORTICOIDS AND ANTI-OSTEOPOROTIC TREATMENT ON BONE HEALTH IN PATIENTS WITH INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISEASES (IRMD)"
- EULAR 2023 oral communication entitled: "PROPORTION OF PATIENTS REACHING THE BONE MINERAL DENSITY (BMD) SURROGATE THRESHOLD EFFECT (STE) WITH BISPHOSPHONATES, DENOSUMAB AND TERIPARATIDE"
- SIOMMMS 2023 oral communication entitled: "MACHINE LEARNING TO CHARACTERIZE BONE PROFILE OF RHEUMATOID ARTHRITIS"
- SIR 2023 oral communication entitled: "IMPACT OF GLUCOCORTICOID DOSING AND ANTI-OSTEOPOROTIC TREATMENT ON BONE HEALTH IN PATIENTS WITH INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISEASES: A LONGITUDINAL COHORT STUDY"
- IOF-WCO-ESCEO 2024 oral presentation entitled: "MACHINE LEARNING TO CHARACTERIZE BONE BIOMARKERS PROFILE IN RHEUMATOID ARTHRITIS"
- ECTS 2024 oral communication entitled: "GLUCOCORTICOID INDUCED OSTEOPOROSIS"
- ECTS 2024 oral communication entitled: "ANOREXIA NERVOSA AND OSTEOPOROSIS, A PROSPECTIVE OBSERVATIONAL STUDY"
- ECTS 2024 oral communication entitled: "ROMOSOZUMAB AND DENOSUMAB COMBINATION STUDY A 6-MONTH PROSPECTIVE OBSERVATIONAL STUDY"
- ECTS 2024 oral communication entitled: "ROMOSOZUMAB EFFECTS ON 3D SHAPER PARAMETERS"
- EULAR 2024 oral communication entitled: "MACHINE LEARNING TO CHARACTERIZE BONE BIOMARKERS PROFILE IN RHEUMATOID ARTHRITIS"
- SIR 2024 oral presentation entitled: "MACHINE LEARNING TO CHARACTERIZE BONE BIOMARKERS PROFILE IN RHEUMATOID ARTHRITIS"
- IOF-WCO-ESCEO 2025 oral presentation entitled: "GLUCOCORTICOIDS, PRESENT AND FUTURE"
- IOF-WCO-ESCEO 2025 oral presentation entitled: "ROMOSOZUMAB AND DENOSUMAB COMBINATION STUDY, A 12-MONTH PROSPECTIVE STUDY"
- EULAR 2025 oral presentation entitled: "ROMOSOZUMAB AND DENOSUMAB COMBINATION STUDY, A 12-MONTH PROSPECTIVE STUDY"

- EULAR 2025 oral presentation entitled: "RATES OF CONCURRENT BMD RESPONSES AT THE LUMBAR SPINE AND TOTAL HIP IN PATIENTS RECEIVING ROMOSOUZMAB OR TERIPARATIDE FOLLOWING BISPHOSPHONATE THERAPY: A POST HOC ANALYSIS OF THE RANODOMISED PHASE 3 STRUCTURE TRIAL"
- EULAR 2025 oral presentation entitled: "ROMOSOZUMAB AND DENOSUMAB COMBINATION STUDY, A 12-MONTH PROSPECTIVE STUDY"
- ACR 2025 oral presentation entitled: "ROMOSOZUMAB AND DENOSUMAB COMBINATION STUDY IN POST MENOPAUSAL OSTEOPOROSIS"

Grants

Current Research

Grant: Sponsorship to research for young researchers

Name of Funding Organization: Società Italiana di Reumatologia (SIR)

Amount Awarded: 25,000 euros

Period of Grant Award: 2021

Title of Project: Update of the deFRACalc79 fracture risk estimation algorithm for imminent risk and longitudinal analysis of the database regarding the therapeutic appropriateness of osteoporosis in Italy

Role on Project: Principal Investigator

Grant: Investigator Initiated study: AMGEN

Name of Funding Organization: Amgen

Amount Awarded: 1,250,000 US dollars

Period of Grant Award: 2020-2024

Title of Project: Denosumab discontinuation and switching in glucocorticoid-induced osteoporosis: a pilot study

Role on Project: Sub-Investigator, Site lead investigator

Grant: Sponsorship to research on environmental pollution

Name of Funding Organization: FEMM - Fondazione Eni Enrico Mattei

Amount Awarded: 5,000 euros

Period of Grant Award: 2022

Title of Project: Exploring the association between acute exposure to air pollutants and the risk of rheumatic musculoskeletal diseases

Role on Project: Principal Investigator

Grant: Sponsorship to research on osteoporosis and environment

Name of Funding Organization: Fondazione Osteoporosi – FGP

Amount Awarded: 5,000 euros

Period of Grant Award: 2022

Title of Project: Association between exposure to fine particulate matter and osteoporosis: a population-based cohort study

Role on Project: Principal Investigator

Grant: Sponsorship for the writing of the guidelines for vaccination in RMDs of the Italian Society of Rheumatology (SIR)

Name of Funding Organization: Società Italiana di Reumatologia (SIR)

Amount Awarded: 4,000 euros

Period of Grant Award: 2023

Title of Project: Italian Society of Rheumatology Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases

Grant: PNRR-MCNT1-2023-12378269

Name of Funding Organization: Italian Ministry of Health (MOH)

Amount Awarded: 1,000,000 euros

Period of Grant Award: 2024-2026

Title of Project: Deciphering the association between acute exposure to environmental air pollution and the risk of rheumatoid arthritis flares

Grant: GRAPPA competitive grant
Name of Funding Organization: GRAPPA
Amount Awarded: 35,000 euros
Period of Grant Award: 2024
Title of Project: Bone Properties and Biomechanics in Patients with Psoriatic Disease: A Prospective Study with High-Resolution Peripheral Quantitative Computed Tomography (HRpQCT)

Grant: Investigator Initiated study: GALAPAGOS – ALFA SIGMA
Name of Funding Organization: GALAPAGOS – ALFA SIGMA
Amount Awarded: 100,000 euros
Period of Grant Award: 2024
Title of Project: Exploring the effects of Filgotinib, an oral JAK-1 selective inhibitor, proteomic profile and micro-RNA expression in peripheral blood mononuclear cell (PBMC) of patients with active rheumatoid arthritis (RA)

Grant: Research Collaboration: UCB Pharma
Name of Funding Organization: UCB Pharma
Amount Awarded: 25.000 euros
Period of Grant Award: 2025
Title of Project: ROMosozumab Early experience in female patients with severe Osteoporosis in Italian real-world setting, the ROMEO study

Grant: Investigator Initiated study: UCB Pharma
Name of Funding Organization: UCB Pharma
Amount Awarded: 651,396 euros
Period of Grant Award: 2026-2027
Title of Project: Romosozumab or teriparatide for glucocorticoid induced osteoporosis (GIOP) a randomized controlled trial

Grant: Fondo Italiano Scienza (FIS) 2023
Name of the Funding Organization: Ministry of University (MIUR)
Amount Awarded: 1.321.689,16 euros
Period of Grant Award: 2025-2028
Title of Project: Deciphering the complex interplay between glucocorticoids, inflammation and bone health in inflammatory rheumatic musculoskeletal diseases (GC-iRMD) - FIS-2023-03632 - CUP B53C25002990001

Awards

I won the award for best young researcher of the international society of osteoporosis: 2020 ESCCEO-IOF Young Investigator Award
I won the award for best oral communication at the XIV Congress OrtoMed 2019
I won the travel award for best young researcher at the EULAR congress 2020
I won the award for best oral communication at the XX Congress SIOMMMS 2020
I won the award for best oral communication at the 57° Congress SIR 2020
I won the award for best oral communication at the XXI Congress SIOMMMS 2021
I won the award for best young researcher of the international society of osteoporosis: 2021 ESCCEO-IOF Young Investigator Award
I won the award for best young researcher: 2021 ECTS –Bone Reports New Investigator Award
I won the travel award for best young researcher at the EULAR congress 2021
I won the award for best clinical abstract at the EULAR congress 2021
I won the award “Paladini della Salute” at the Campidoglio October 2021, Rome
I won the award for best oral communication at the 58° Congress SIR 2021
I won the award for best young researcher of the international society of osteoporosis: 2022 ESCCEO-IOF Young Investigator Award

I won the travel award for best young researcher at the EULAR congress 2022
I won the travel award for best young researcher at the ASBMR congress 2022
I won the award for best oral communication at the XXII Congress SIOMMMS 2022
I won the travel award for best young researcher at the EULAR congress 2023
I won the 2024 ASBMR young investigator award at the ASBMR congress 2024
I won the 2025 ECTS young investigator award at the ECTS congress 2025
I won the 2025 EULAR travel award for young investigators

Spoken languages

Italian (native speaker)
English – spoken C1, written C1

Digital skills

Excellent mastery of common operating systems and writing software (e.g., Word), calculation/database (e.g., Excel/Access), PowerPoint. Excellent knowledge of statistical software (IBM SPSS, GraphPad Prism, JASP and R).

Membership in groups/associations

European Calcified Tissue Society (ECTS) Academy member (2023-2025)
Italian Society of Rheumatology (SIR)
SIRyoung under 40 – Member of the Steering Committee 2022-2024 and 2024-2026
Emerging Eular Network (EMEUNET)
Italian Society of Osteoporosis and Mineral Metabolism and Skeletal Diseases (SIOMMMS)
YES! (Young Edition SIOMMMS) under 35 – National coordinator of Gruppo YES
Italian Society for Unified and Interdisciplinary Management of Musculoskeletal Pain and Algodystrophy (GUIDA)
European Calcified Tissue Society (ECTS)
European Alliance of Association for Rheumatology (EULAR) Blue Member
Convenor of the EULAR project QoC026 for the development of recommendations for the screening and management of osteoporosis in patients with inflammatory rheumatic musculoskeletal diseases (iRMDs)
American College of Rheumatology (ACR) fellow
American Society of Bone and Mineral Research (ASBMR) – Member of the membership engagement committee

*I authorize the processing of my personal data present in the CV pursuant to art. 13 of legislative decree 30 June 2003, n. 196 "Code on the protection of personal data" and art. 13 of the GDPR (EU Regulation 2016/679)
The information contained in this CV is true and the statements made in the curriculum are issued pursuant to Articles 46 and 47 of Presidential Decree No. 445/2000*

Verona, 10 Nov 2025
Dr. Giovanni Adami